Revolution Medicines, Inc. $RVMD Shares Bought by Vanguard Group Inc.

Key Points

• Vanguard Group raised its position in Revolution Medicines by 6.7% in Q4 to 16,719,886 shares (about 8.65% ownership), adding 1,056,792 shares and valuing its stake at roughly $1.33 billion.
• Corporate insiders have been net sellers, offloading 184,592 shares worth about $24.5 million over the past 90 days (including recent sales by Xiaolin Wang and Stephen M. Kelsey); insiders now own about 8.20% of the company.
• Sell‑side analysts are broadly positive with a consensus Buy rating and an average target of $78.94, despite a recent quarterly EPS miss; the stock is trading near $144 with a $30.6 billion market cap and a 12‑month range of $34.00–$155.70.

Vanguard Group Inc. raised its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,719,886 shares of the company's stock after acquiring an additional 1,056,792 shares during the period. Vanguard Group Inc. owned approximately 8.65% of Revolution Medicines worth $1,331,739,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Revolution Medicines by 194.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,289 shares of the company's stock valued at $1,696,000 after acquiring an additional 14,062 shares during the period. New York State Common Retirement Fund lifted its position in Revolution Medicines by 39.3% during the third quarter. New York State Common Retirement Fund now owns 119,807 shares of the company's stock valued at $5,595,000 after purchasing an additional 33,821 shares during the period. Raiffeisen Bank International AG bought a new stake in shares of Revolution Medicines during the 3rd quarter valued at about $921,000. Mass General Brigham Inc purchased a new stake in shares of Revolution Medicines in the 4th quarter worth $27,407,000. Finally, NEOS Investment Management LLC raised its stake in Revolution Medicines by 34.7% during the 3rd quarter. NEOS Investment Management LLC now owns 126,921 shares of the company's stock worth $5,927,000 after acquiring an additional 32,694 shares during the period. Institutional investors and hedge funds own 94.34% of the company's stock.

Insiders Place Their Bets

In other news, insider Xiaolin Wang sold 2,010 shares of the company's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the transaction, the insider directly owned 116,063 shares of the company's stock, valued at $11,545,947.24. This represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Stephen Michael Kelsey sold 4,302 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $427,962.96. Following the sale, the insider owned 295,398 shares in the company, valued at approximately $29,386,193.04. The trade was a 1.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 184,592 shares of company stock worth $24,499,532. Corporate insiders own 8.20% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on RVMD. UBS Group assumed coverage on Revolution Medicines in a research report on Friday, February 27th. They issued a "buy" rating on the stock. Truist Financial upgraded Revolution Medicines to a "strong-buy" rating in a report on Monday. Evercore restated an "outperform" rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Jefferies Financial Group began coverage on shares of Revolution Medicines in a report on Monday, March 16th. They issued a "buy" rating for the company. Finally, Wedbush reaffirmed an "outperform" rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $78.94.

Revolution Medicines Price Performance

RVMD opened at $144.12 on Friday. The firm has a market cap of $30.64 billion, a price-to-earnings ratio of -24.39 and a beta of 1.01. Revolution Medicines, Inc. has a 12-month low of $34.00 and a 12-month high of $155.70. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. The stock's 50-day moving average price is $110.80 and its 200 day moving average price is $91.79.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period in the prior year, the firm posted ($1.12) earnings per share. As a group, sell-side analysts expect that Revolution Medicines, Inc. will post -7.42 earnings per share for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.